5 Key Takeaways
-
1
Systems review evaluates over 100 publications on dry eye disease treatments.
-
2
Shift from lubrication to mechanism-targeted therapies noted in past decade.
-
3
Anti-inflammatory agents demonstrate strong efficacy.
-
4
Disconnect between objective improvement and patient-reported symptoms emphasized.
-
5
Identification of DED mechanism helps in therapy selection.
The systematic review by Clara C. Chan and colleagues evaluates over 100 publications to analyze current topical pharmacologic treatments for dry eye disease (DED). This review highlights a shift from lubrication to mechanism-targeted therapies over the past decade, noting the efficacy of anti-inflammatory agents and new formulations such as cyclopsorine and lifitegrast. While objective improvements in DED symptoms like corneal staining are common, patient-reported symptom relief remains inconsistent, underscoring the need for tailored treatment strategies and multidisciplinary approaches in DED management.
Listen Tab content
